Share Prices & Company Research

Market News

12 Mar 2019 | 13:07

Smith & Nephew acquires Osiris Therapeutics for around $660m

Medical technology company Smith & Nephew said it had agreed to acquire regenerative medicine group Osiris Therapeutics for around $660m.

Osiris Therapeutics offered products including skin, bone graft and articular cartilage substitutes.

Smith & Nephew offered $19.00 cash per Osiris Therapeutics share.

'Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business as well as provide longer term innovations in additional channels and indications,' chief executive Namal Nawana said.

'We sought out a fast growing portfolio with strong clinical evidence addressing critical needs in the marketplace.'

Osiris posted revenue of $102m for the nine-months through September, up 19% on-year.

At 1:07pm: (LON:SN.) Smith Nephew PLC share price was +19.75p at 1481.75p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.